Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03709576 · ClinicalTrials.gov registry record · Phase 2
Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML
A Phase 2 study, sponsored by Milton S. Hershey Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03709576: Clinical Trial Phase 2 study, sponsored by Milton S. Hershey Medical Center.
NCT03709576 is a Phase 2 study that was terminated before completion, run by Milton S. Hershey Medical Center. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03709576, a Phase 2 study, was terminated before completion, sponsored by Milton S. Hershey Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This research is being done to find out the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML and to see the overall diseases free survival, relapse, and GVHD after treatment.
Primary Outcome
One year overall survival assess by Kaplan Meier Plots
Interventions
- DRUG Azacitidine
- DRUG Pevonedistat
- PROCEDURE transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-07-18 |
| Est. Completion | 2019-07-22 |
| Phase | Phase 2 |
Why NCT03709576 stopped before completion
NCT03709576 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Azacitidine is the first listed.
NCT03709576 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03709576 about?
NCT03709576 is a clinical study titled "Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML". This research is being done to find out the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML and to see the overall diseases free survival, relapse, and GVHD after treatment.
What is the current status of trial NCT03709576?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2018-07-18. Estimated completion is 2019-07-22.
What interventions are being tested in trial NCT03709576?
The interventions under investigation include: Azacitidine (DRUG), Pevonedistat (DRUG), transplant (PROCEDURE).
Who is sponsoring clinical trial NCT03709576?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03709576's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI